EU-Funded Cultivated Meat Tech Targets Muscle Wasting in GLP-1 Therapy Patients

ProFuse Technology’s cultivated meat research aims to counteract muscle loss in diabetes patients using weight-loss drugs.

ProFuse Technology secured €2.4 million ($2.8 million) in European Innovation Council funding to advance cultivated meat inputs targeting muscle wasting in GLP-1 therapy users. This research addresses a specific clinical challenge: patients on weight-loss drugs like Ozempic and Mounjaro experience 25-40% muscle mass reduction over 8 to 16 months, worsening diabetes management. ProFuse developed two proprietary cell lines—ProFuse-S1 (accelerating muscle maturation) and ProFuse-S2 (a non-GMO bovine line)—which Israeli startup SuperMeat tested for cost reductions, and a Dutch company confirmed successful adaptation of the bovine cell line. The project builds on earlier European Research Council work and aligns with Upside Foods’ Lucius Labs launch in January 2026.

The mechanism centers on engineered muscle cells that could stabilize muscle mass for GLP-1 users, potentially reducing complications from weight-loss therapy. If commercialized, ProFuse’s inputs might lower healthcare burdens tied to muscle wasting while advancing cultivated meat scalability. Current validation shows early promise in production costs and cross-border adaptation, but the products remain under development.

This moves abundance for diabetes patients by addressing a critical quality-of-life barrier in GLP-1 therapy—muscle loss that complicates blood sugar control. By potentially mitigating this side effect, the technology could improve treatment adherence and reduce long-term healthcare strain. However, the impact hinges on clinical validation and commercialization timelines.

What to watch: ProFuse’s path to clinical trials for GLP-1 users, as the current market projection of €22 billion ($25.7 billion) by 2050 is unverified. Muscle mass reduction figures apply exclusively to Ozempic/Mounjaro users, and neither ProFuse-S1 nor S2 are yet commercialized. The source provides limited detail on real-world patient outcomes or cost savings beyond initial pilot data.

Source: Green Queen